CorVel vs Sotera Health
Add, change or remove companies; up to four.
KIRAβs take AI analyst
I put CorVel and Sotera Health side by side, using each oneβs latest annual report. Here is what stands out:
- Sotera Health is the larger business, with $1.2B of revenue in fiscal 2025 against $959M for CorVel.
- CorVel grew revenue faster (7.0%, against 5.7%).
- Sotera Health turned more of its sales into free cash flow (12.8% FCF margin, against 11.5%).
- Investors pay more for each dollar of CorVelβs earnings: a P/E of 37.3x against 31.8x for Sotera Health.
Who comes out ahead
Of the 7 measures where higher (or lower) is clearly better, how many each company leads.
CorVel
CRVL
5/7
Revenue growth5-year growthNet marginReturn on equityShare count change
Sotera Health
SHC
2/7
Gross marginFCF margin
Side by side
Best in the row
| Latest fiscal year | CRVL FY26 | SHC FY25 |
|---|---|---|
| Size | ||
| Market cap | $4.3B | $5.2B |
| Revenue | $959M | $1.2B |
| Free cash flow | $110M | $149M |
| Net income | $110M | $77.9M |
| Growth | ||
| Revenue growth | 7.0% | 5.7% |
| 5-year growth | 11.6% | 7.3% |
| Share count change | β0.7% | 0.5% |
| Profitability | ||
| Gross margin | 24.3% | 55.5% |
| Operating margin | β | β |
| Net margin | 11.5% | 6.7% |
| FCF margin | 11.5% | 12.8% |
| Return on capital | β | 6.7% |
| Return on equity | 30.8% | 15.4% |
| Balance sheet | ||
| Net debt | β | $1.9B |
| Net debt / EBITDA | β | β |
| Dividends and buybacks | $56.2M | $0.0M |
| Valuation & quality | ||
| P/E | 37.3x | 31.8x |
| Piotroski F-score | β | 7 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.